                         SEQUENCE LISTING

<110>  Neurimmune Holding AG
       University of Zurich
 
<120>  Novel compounds capable of antagonizing islet amyloid polypeptide
        (IAPP) induced beta()-cell damage and impaired glucose 
       tolerance

<130>  NE30A48/P-WO

<150>  EP14159194.1
<151>  2014-03-12

<160>  7     

<170>  PatentIn version 3.5

<210>  1
<211>  363
<212>  DNA
<213>  Homo sapiens


<220>
<221>  CDS
<222>  (1)..(363)
<223>  NI-203.26C11-VH variable heavy chain (VH) sequence

<220>
<221>  V_region
<222>  (76)..(111)
<223>  complementarity determining region (CDR) VH-CDR1

<220>
<221>  V_region
<222>  (154)..(201)
<223>  complementarity determining region (CDR) VH-CDR2

<220>
<221>  V_region
<222>  (298)..(330)
<223>  complementarity determining region (CDR) VH-CDR3

<400>  1
cag gtg cag ctg cag gag tcg ggc cca gga ttg gtg aag cct tct cag         48
Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Gln           
1               5                   10                  15                

acc ctg tcc ctc acc tgc act gtc tct ggt ggc tcc atc agc agt ggt         96
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Gly           
            20                  25                  30                    

aat tac tac tgg acc tgg atc cgg cag ccc gcc ggg aag gga ctg gag        144
Asn Tyr Tyr Trp Thr Trp Ile Arg Gln Pro Ala Gly Lys Gly Leu Glu           
        35                  40                  45                        

tgg att ggg cat atc tat tcc agt ggg acc acc aat tac aac ccc tcc        192
Trp Ile Gly His Ile Tyr Ser Ser Gly Thr Thr Asn Tyr Asn Pro Ser           
    50                  55                  60                            

ctc gag agt cga gtc acc att tca gta gac acg tcc aag aac cag ttc        240
Leu Glu Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe           
65                  70                  75                  80            

tcc ctg agc ctg aac tct gtg acc gcc gca gac acg gcc gtt tat tac        288
Ser Leu Ser Leu Asn Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr           
                85                  90                  95                

tgt gcg aga cca ctg gct aca gtt ccg gat gct ttt aat atc tgg ggc        336
Cys Ala Arg Pro Leu Ala Thr Val Pro Asp Ala Phe Asn Ile Trp Gly           
            100                 105                 110                   

caa ggg aca atg gtc acc gtc tct tcg                                    363
Gln Gly Thr Met Val Thr Val Ser Ser                                       
        115                 120                                           


<210>  2
<211>  121
<212>  PRT
<213>  Homo sapiens

<400>  2

Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Gln 
1               5                   10                  15      


Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Gly 
            20                  25                  30          


Asn Tyr Tyr Trp Thr Trp Ile Arg Gln Pro Ala Gly Lys Gly Leu Glu 
        35                  40                  45              


Trp Ile Gly His Ile Tyr Ser Ser Gly Thr Thr Asn Tyr Asn Pro Ser 
    50                  55                  60                  


Leu Glu Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe 
65                  70                  75                  80  


Ser Leu Ser Leu Asn Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr 
                85                  90                  95      


Cys Ala Arg Pro Leu Ala Thr Val Pro Asp Ala Phe Asn Ile Trp Gly 
            100                 105                 110         


Gln Gly Thr Met Val Thr Val Ser Ser 
        115                 120     


<210>  3
<211>  333
<212>  DNA
<213>  Homo sapiens


<220>
<221>  CDS
<222>  (1)..(333)
<223>  NI-203.26C11-VK variable kappa-light chain (VK) sequence

<220>
<221>  V_region
<222>  (70)..(114)
<223>  complementarity determining region (CDR) VK-CDR1

<220>
<221>  V_region
<222>  (160)..(180)
<223>  complementarity determining region (CDR) VK-CDR2

<220>
<221>  V_region
<222>  (277)..(303)
<223>  complementarity determining region (CDR) VK-CDR3

<400>  3
gaa att gtg atg act cag tct cca gac tcc ctg gct gtg tct ctg ggc         48
Glu Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly           
1               5                   10                  15                

gag agg gcc acc atc aag tgc aag tcc agc cag agt gtt tta tac agc         96
Glu Arg Ala Thr Ile Lys Cys Lys Ser Ser Gln Ser Val Leu Tyr Ser           
            20                  25                  30                    

aat aag aac ttc tta gct tgg tac cag cag aaa cca gga cag cct cct        144
Asn Lys Asn Phe Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro           
        35                  40                  45                        

aaa tta ctc att tac tgg gca tct act cgg gaa tcc ggg gtc cct gac        192
Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val Pro Asp           
    50                  55                  60                            

cga ttc agt ggc agc ggg tct ggg aca gat ttc act ctc acc atc agc        240
Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser           
65                  70                  75                  80            

agc ctg cag gct gaa gat gtg gca gtt tat tac tgt cag cag tat tat        288
Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln Tyr Tyr           
                85                  90                  95                

agt aat cct aac act ttt ggc cag ggg acc aag gtg gag atc aaa            333
Ser Asn Pro Asn Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys               
            100                 105                 110                   


<210>  4
<211>  111
<212>  PRT
<213>  Homo sapiens

<400>  4

Glu Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly 
1               5                   10                  15      


Glu Arg Ala Thr Ile Lys Cys Lys Ser Ser Gln Ser Val Leu Tyr Ser 
            20                  25                  30          


Asn Lys Asn Phe Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro 
        35                  40                  45              


Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val Pro Asp 
    50                  55                  60                  


Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser 
65                  70                  75                  80  


Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln Tyr Tyr 
                85                  90                  95      


Ser Asn Pro Asn Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 
            100                 105                 110     


<210>  5
<211>  333
<212>  DNA
<213>  Homo sapiens


<220>
<221>  CDS
<222>  (1)..(333)
<223>  NI-203.26C11-VK PIMC variable kappa-light chain (VK) sequence

<220>
<221>  V_region
<222>  (70)..(114)
<223>  complementarity determining region (CDR) VK-CDR1

<220>
<221>  V_region
<222>  (160)..(180)
<223>  complementarity determining region (CDR) VK-CDR2

<220>
<221>  V_region
<222>  (277)..(303)
<223>  complementarity determining region (CDR) VK-CDR3

<400>  5
gat att gtg atg act caa tca cca gac tcc ctg gct gtg tct ctg ggc         48
Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly           
1               5                   10                  15                

gag agg gcc acc atc aag tgc aag tcc agc cag agt gtt tta tac agc         96
Glu Arg Ala Thr Ile Lys Cys Lys Ser Ser Gln Ser Val Leu Tyr Ser           
            20                  25                  30                    

aat aag aac ttc tta gct tgg tac cag cag aaa cca gga cag cct cct        144
Asn Lys Asn Phe Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro           
        35                  40                  45                        

aaa tta ctc att tac tgg gca tct act cgg gaa tcc ggg gtc cct gac        192
Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val Pro Asp           
    50                  55                  60                            

cga ttc agt ggc agc ggg tct ggg aca gat ttc act ctc acc atc agc        240
Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser           
65                  70                  75                  80            

agc ctg cag gct gaa gat gtg gca gtt tat tac tgt cag cag tat tat        288
Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln Tyr Tyr           
                85                  90                  95                

agt aat cct aac act ttt ggc cag ggg acc aag ctg gag atc aag            333
Ser Asn Pro Asn Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys               
            100                 105                 110                   


<210>  6
<211>  111
<212>  PRT
<213>  Homo sapiens

<400>  6

Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly 
1               5                   10                  15      


Glu Arg Ala Thr Ile Lys Cys Lys Ser Ser Gln Ser Val Leu Tyr Ser 
            20                  25                  30          


Asn Lys Asn Phe Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro 
        35                  40                  45              


Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val Pro Asp 
    50                  55                  60                  


Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser 
65                  70                  75                  80  


Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln Tyr Tyr 
                85                  90                  95      


Ser Asn Pro Asn Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys 
            100                 105                 110     


<210>  7
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  unique linear epitope recognized by antibody NI-203.26C11 aa 2 to
       8

<400>  7

Cys Asn Thr Ala Thr Cys Ala 
1               5           


